The Role of Eicosanoids in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders known. Estimates from the Alzheimer’s Association suggest that there are currently 5.8 million Americans living with the disease and that this will rise to 14 million by 2050. Research over the decades has revealed that AD pathology is complex and involves a number of cellular processes. In addition to the well-studied amyloid-β and tau pathology, oxidative damage to lipids and inflammation are also intimately involved. One aspect all these processes share is eicosanoid signaling. Eicosanoids are derived from polyunsaturated fatty acids by enzymatic or non-enzymatic means and serve as short-lived autocrine or paracrine agents. Some of these eicosanoids serve to exacerbate AD pathology while others serve to remediate AD pathology. A thorough understanding of eicosanoid signaling is paramount for understanding the underlying mechanisms and developing potential treatments for AD. In this review, eicosanoid metabolism is examined in terms of in vivo production, sites of production, receptor signaling, non-AD biological functions, and known participation in AD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589 · cited 1×
“In keeping with PGI2 neuroprotection, PGI2 has also been observed to protect mouse brain pericytes from lysophosphatidylcholine (LPV)-mediated apoptosis [93] thereby preventing BBB disruption, a known characteristic of AD [94], and AD-like neurodegeneration in mice [95].”
BackgroundRetractedLipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate
Brash, A. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23679 · Cited by 1,335 · cited 1×
“The HETE family of molecules and their unstable precursors, the hydroperoxyeicosatetraenoic acids (HPETEs), are notable as precursors for the leukotriene family, lipoxin family, trioxilin family, and eoxin family of metabolites, as well serving as signaling molecules in their own right [153].”
BackgroundThe role of inflammation in CNS injury and disease
Lucas, S., Rothwell, N. J., & Gibson, R. M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706400 · Cited by 1,272
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · cited 1×
“For example, in a population-based cohort study of 6989 subjects 55 years or older living in Ommoord, Netherlands, long term use of NSAIDs (24 months or more) reduced the relative risk of AD by 80% [37].”
BackgroundHong, S., Gronert, K., Devchand, P. R., Moussignac, R.-L., & Serhan, C. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300218200 · Cited by 1,000
Resolvins and protectins in inflammation resolution
Serhan, C. N., & Petasis, N. A. (2011) · Chemical Reviews · doi:10.1021/cr100396c · Cited by 996
Sleep and Alzheimer disease pathology--a bidirectional relationship
Ju, Y.-E. S., Lucey, B. P., & Holtzman, D. M. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.269 · Cited by 996
Dyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
Praticò, D., Uryu, K., Leight, S., Trojanoswki, J. Q., & Lee, V. M.-Y. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04183.2001 · Cited by 777 · cited 1×
“A second study monitored urinary, plasma, and brain homogenate 8,12-iso-iPF2α-VI from Tg2576 mice and found that concentrations were higher in Tg2576 mice than WT as early as eight months of age [138].”
Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M., & Kudo, I. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003504200 · Cited by 708 · cited 1×
“Prostaglandin E2 (PGE2, (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5oxocyclopentyl]hept-5-enoic acid) is synthesized from PGH2 by microsomal PGE2 synthase-1 (PTGES, mPGES-1), microsomal PGE2 synthase-2 (PTGES2, mPGES-2), and cytoplasmic PGES-3 (PTGES3, cPGES), each having a different structure and seve…”
BackgroundCaspase-cleavage of tau is an early event in Alzheimer disease tangle pathology
Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420640 · Cited by 543 · cited 2×
“This was followed by activation of caspase cleavage of tau at D141, leading to the production of ∆tau, an early event in AD pathology [72].”
BackgroundContribution of inflammatory processes to Alzheimer's disease: molecular mechanisms
Sastre, M., Klockgether, T., & Heneka, M. T. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.014 · Cited by 426 · cited 1×
“Activated microglia are also reported to be major producers of the prostaglandin PGE2 through the COX-2 pathway [13] and serve as a trigger for uncontrolled astrocyte proliferation [14], another feature of AD [15].”
BackgroundIncreased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405
Resolution of inflammation is altered in Alzheimer's disease
Wang, X., Zhu, M., Hjorth, E., Cortés‐Toro, V., Eyjolfsdottir, H., Graff, C., Nennesmo, I., Palmblad, J., Eriksdotter, M., Sambamurti, K., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.024 · Cited by 301 · cited 7×
“This receptor is abundantly expressed in monocytes in lower amounts in neutrophils and T lymphocytes [231] as well as in pyramidal cells, neurons, astrocytes, and microglia [207].”
BackgroundResultInfluentialAmyloid β42Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1
Le, Y., Gong, W., Tiffany, H. L., Tumanov, A., Nedospasov, S., Shen, W., Dunlop, N. M., Gao, J.-L., Murphy, P. M., Oppenheim, J. J., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-j0003.2001 · Cited by 270
Acetaminophen and the Cyclooxygenase-3 Puzzle: Sorting out Facts, Fictions, and Uncertainties
Kis, B., Snipes, J. A., & Busija, D. W. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085431 · Cited by 250 · cited 1×
“A third isoform (COX-3, COX-1b), a splice variant of COX-1, has been identified in humans and other mammals, but its involvement in human prostaglandin synthesis has largely been discounted [29].”
BackgroundZhao, Y., Calon, F., Julien, C., Winkler, J. W., Petasis, N. A., Lukiw, W. J., & Bazan, N. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015816 · Cited by 243 · cited 3×
“This down-regulation of COX-2 and B94 was facilitated through suppression of β-secretase-1, activation of α-secretase and up-regulation sAPPα.”
BackgroundMolecular mechanisms of sleep‐wake regulation: roles of prostaglandins D 2 and E 2
Hayaishi, O. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907936 · Cited by 235
Nathan, C., Calingasan, N., Nezezon, J., Ding, A., Lucia, M. S., La Perle, K., Fuortes, M., Lin, M., Ehrt, S., Kwon, N. S., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051529 · Cited by 214
Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis
Zhu, M., Wang, X., Hjorth, E., Colas, R. A., Schroeder, L., Granholm, A.-C., Serhan, C. N., & Schultzberg, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9544-0 · Cited by 204 · cited 4×
“Reports have indicated that MaR1 may be the most potent of the SPMs in resolution of inflammation [228].”
BackgroundInfluentialAβ-peptides enhance vasoconstriction in cerebral circulation
Niwa, K., Porter, V. A., Kazama, K., Cornfield, D., Carlson, G. A., & Iadecola, C. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.6.h2417 · Cited by 202
Medeiros, R., Kitazawa, M., Passos, G. F., Baglietto-Vargas, D., Cheng, D., Cribbs, D. H., & LaFerla, F. M. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.051 · Cited by 163
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models
Johansson, J. U., Woodling, N. S., Wang, Q., Panchal, M., Liang, X., Trueba-Saiz, A., Brown, H. D., Mhatre, S. D., Loui, T., & Andreasson, K. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77487 · Cited by 161 · cited 2×
“Further, with aging or Aβ42 accumulation, microglial EP2 has been shown to be upregulated, increasing pro-inflammatory gene expression, suppressing beneficial chemokine production, chemotaxis [109], and phagocytosis [119]; at the same time EP4 expression was reduced.”
BackgroundNSAIDs and incident Alzheimer’s disease. The Rotterdam study
In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00096-7 · Cited by 145 · cited 3×
“Non-steroidal anti-inflammatory agents (NSAIDs) are known inhibitors of cyclooxygenases and there are numerous reports that show unequivocally that long term use of NSAIDs is associated with a reduction in the risk of developing AD [35,36].”
BackgroundKantarci, A., Aytan, N., Palaska, I., Stephens, D., Crabtree, L., Benincasa, C., Jenkins, B. G., Carreras, I., & Dedeoglu, A. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.11.005 · Cited by 118
Salic, K., Morrison, M. C., Verschuren, L., Wielinga, P. Y., Wu, L., Kleemann, R., Gjorstrup, P., & Kooistra, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.001 · Cited by 105 · cited 1×
“An unpublished clinical study revealed an overall half-life for RvE1 of 7 h [230].”
BackgroundHoozemans, J. J., van Haastert, E. S., Veerhuis, R., Arendt, T., Scheper, W., Eikelenboom, P., & Rozemuller, A. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-27 · Cited by 52 · cited 1×
“PGH2 through the action of hematopoietic prostaglandin D synthase (HPGDS) and the lipocalin-type prostaglandin D synthase (PTGDS, L-PGDS), the latter shown to be one of the more abundant proteins in the brain [54].”
Cited by
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“The affection of prostaglandins and thromboxanes signaling on neurodegeneration has been reviewed recently.(423,424) Here we will mainly focus on the recent development on SPMs.”
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
“Eicosanoids Pro-inflammatory eicosanoid pathways are upregulated in AD individuals, while anti-inflammatory eicosanoids are decreased (Biringer, 2019).”
BackgroundThe Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease
Ogunmokun, G., Dewanjee, S., Chakraborty, P., Valupadas, C., Chaudhary, A., Kolli, V., Anand, U., Vallamkondu, J., Goel, P., Paluru, H. P. R., et al. (2021) · Cells · doi:10.3390/cells10102790 · Cited by 85
Chen, K., Chen, Y., Ren, Y., Wang, Z., Huang, Y., Pan, M., Li, Z., Casey, M. C., Qiao, W., Shi, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-78407-x
Metadata
- Authors
- Biringer, R. G.
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2019-07-18
- Volume
- 16
- Issue
- 14
- Pages
- 2560
- ISSN
- 1660-4601 (ISSN-L)
- OpenAlex
- W2956297634
- Cited by
- 64
- References
- 27
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.